Wake Forest / 23.05.2013
MedicalResearch.com eInterview with Dr. Giuseppe Orlando, M.D., Ph.D.
Dr. William A. Bauman, MD
Veterans Affairs Rehabilitation Research and Development
National Center of Excellence for the Medical Consequences of Spinal Cord Injury
Suite 7A-13, James J. Peters Veterans Affairs Medical Center
130 West Kingsbridge Road, Bronx, NY 10468;
MedicalResearch.com: What are the main findings of the study?
Dr. Bauman: In a prospective, randomized two-group, double-blind, placebo-controlled, intention-to-treat clinical trial, we determined whether SCI in-patients with a full thickness (Stage III or IV) pressure ulcers of the pelvic region who received 24 weeks or less of optimized clinical care and an oral anabolic steroid agent, oxandrolone, have a greater percent of healed target pressure ulcers than those who received placebo and the same clinical care. There was no significant difference in proportion of pressure ulcers that healed between the treatment and placebo groups [treatment recipients 24.1% (95% CI, 16.0% to 32.1%) and placebo recipients 29.8% (CI, 21% to 38.6%) with a difference, -5.7 percentage points (CI, -17.5 to 6.8 percentage points)]. Also, the rate of healing of wounds at 28 days was not significantly different between the groups (50.9% of the oxandrolone group and 43.3% of the placebo group had healing of ≥30.0%), nor was the number of wounds that remained closed at 8 weeks significantly different (16.7% of the oxandrolone group and 15.4% of the placebo group). No serious adverse events were related to drug administration but a significantly greater proportion of patients had elevated liver enzymes in the treatment group [treatment recipients 32.4% (95% CI, 23.6% to 41.2%) and placebo recipients 2.9%% (CI, 0.0% to 6.1%).
Thus, oxandrolone showed no benefit over placebo for improving healing of chronic pressure ulcers of the pelvic region or the proportion that remained closed after 8 weeks of treatment.
MedicalResearch.com eInterview with Luis Beck-da-Silva, MD, ScD Cardiology Division, Heart Failure Clinic Hospital de Clínicas de Porto Alegre Rua Ramiro Barcelos, 2350 Sala...
MedicalResearch.com eInterview with: Christopher J Lindsell, PhD Vice Chair for Research, Department of Emergency Medicine Director of Biostatistics, Epidemiology and Research Design, Center for Clinical...
| MedicalResearch.com eInterview with: Dugald Seely ND, MSc, FABNO Founder & Executive Director; Ottawa Integrative Cancer Centre Director; Research & Clinical Epidemiology; Canadian College of Naturopathic Medicine Affiliate Investigator; Ottawa Hospital Research Institute 29 Bayswater Ave Ottawa, ON, K1Y 2E5 www.oicc.ca |
MedicalResearch.com eInterview with Satya Krishna Ramachandran MD FRCA Director, Quality Assurance Department of Anesthesiology University of Michigan MedicalResearch.com: What are the main findings of the...
MedicalResearch.com eInterview with: M. Kit Degado, MD, MS
Instructor, Emergency Medicine
Affiliated Faculty, Centers for Health Policy/Primary Care and Outcomes Research
Stanford University School of Medicine
kdelgado@stanford.edu
MedicalResearch.com: What are the main findings of the study?
Dr. Degado:
Soo Aleman
Department of Gastroenterology and Hepatology, and Infectious Diseases
Karolinska University Hospital, at Karolinska Institute
171 76 Stockholm, Sweden,
MedicalResearch.com: What are the main findings of the study?
Answer: In this long-term, prospective study of 351 hepatitis C infected patients with liver cirrhosis, we found a reduced but persistent risk for hepatocellular cancer after successful treatment with eradication of the virus. This risk for hepatocellular cancer remained at a level of 1% per year for those with sustained virological response, and could persist as long as 8 years after eradication.
MedicalResearch.com eInterview with
Nancy L. Keating MD, MPH
Harvard Medical School
Department of Health Care Policy
180 Longwood Avenue
Boston, MA 02115-5899
MedicalResearch.com: What are the main findings of the study?
Dr. Keating: We examined data from the 2005, 2008 and 2011 waves of the National Health Interview Survey (NHIS) a national population-based in person survey to assess whether mammography rates changed following the Nov 2009 USPSTF recommendations. Prior to 2009 the USPSTF recommended routine screening every 1-2 years for all women older than 40 years old. In 2009, the USPSTF advised against routine mammography screening in women under 50, and recommended biennial screening for women 50-74.